

Freedom of Information Act 2000 - Request Reference FoI/22/484

Biologic Treatments in Gastroenterology

1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira - 0
- Adalimumab Biosimilar - 29
- Filgotinib - 9
- Golimumab - 0
- Infliximab - Remicade - 0
- Infliximab Biosimilar - 146
- Ozanimod - 0
- Tofacitinib - 1
- Ustekinumab - 20
- Vedolizumab - 164

2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab - Humira - 0
- Adalimumab Biosimilar - 12
- Filgotinib - 9
- Golimumab - 0
- Infliximab - Remicade - 0
- Infliximab Biosimilar - 59
- Ozanimod - 0
- Tofacitinib - 1
- Ustekinumab - 2
- Vedolizumab - 97